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Background: In the past decade, many researchers focused on to robot‑assisted surgery. However, on long‑term 
outcomes for patients with early‑stage non–small cell lung cancer (NSCLC), whether the robotic procedure is superior 
to video‑assisted thoracic surgery (VATS) and thoracotomy is unclear. Nonetheless, in the article titled “Long‑term 
survival based on the surgical approach to lobectomy for clinical stage I non–small cell lung cancer: comparison of 
robotic, video assisted thoracic surgery, and thoracotomy lobectomy” by Yang et al. that was recently published in 
Annals of Surgery, the authors provided convincing evidence that the robotic procedure results in similar long‑term 
survival as compared with VATS and thoracotomy. Minimally invasive procedures typically result in shorter lengths of 
hospital stay, and the robotic procedure in particular results in superior lymph node assessment.
Main body: Our propensity score‑matched study generated high‑quality data. Based on our findings, we see prom‑
ise in expanding patient access to robotic lung resections. In this study, propensity score matching minimized the 
bias involved between groups. Nevertheless, due to its retrospective nature, bias may still exist. Currently, the concept 
of rapid rehabilitation is widely accepted, and it is very difficult to set up a randomized controlled trial to compare 
robotic, VATS, and thoracotomy procedures for the treatment of NSCLC. Therefore, to overcome this limitation and to 
minimize bias, the best approach is to use a registry and prospectively collected, propensity score‑matched data.
Conclusions: Robotic lung resections result in similar long‑term survival as compared with VATS and thoracotomy. 
Robot‑assisted and VATS procedures are associated with short lengths of hospital stay, and the robotic procedure in 
particular results in superior lymph node assessment. Considering the alarming increase in the incidence of lung can‑
cer in China, a nationwide database of prospectively collected data available for clinical research would be especially 
important.
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Background
Lung cancer is the most common malignancy worldwide 
and in China, with surgery being the most effective treat-
ment for patients with early-stage disease [1, 2]. In the 
past decade, many researchers focused on robot-assisted 
surgery. In China, in 2015, there were only approximately 
30 robotic surgical devices; however, just 1  year later, 
in 2016, there are over 50. Although robot-assisted sur-
gery in China is in its infancy, the rapid increase in the 
number of robotic devices suggests that this procedure 
is becoming more and more popular. Considering that 
modern medical care values the concept of rapid reha-
bilitation of patients, it is not surprising that minimally 
invasive procedures, such as robot-assisted surgery, are 
drawing the interest of surgeons.
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Currently, video-assisted thoracic surgery (VATS) is 
considered the most representative minimally invasive 
lobectomy procedure for the treatment of non–small cell 
lung cancer (NSCLC). However, VATS does have its dis-
advantages, such as an only two-dimensional view, cam-
era tremor, and less freedom of instrumentation, resulting 
in a steep learning curve that hinders its widespread use 
[3]. Previous data suggested that although the percent-
age of VATS lung resections has been increasing over the 
past decade, in the 2010s in the United States, for exam-
ple, thoracotomy was used in more than half of cases [4]; 
in China, the percentage of cases in which open thoracot-
omy was used was even larger. Owing to the advantages 
of three-dimensional optics, stable camera platform, and 
flexible instrumentation, the robotic procedure has been 
increasingly used in surgical resection of NSCLC. How-
ever, most previous studies of robotic lobectomy in the 
treatment of NSCLC focused on short-term outcomes, 
such as technique feasibility, surgical complications, and 
costs [5–8]; furthermore, long-term data are limited [9, 
10], and survival comparisons between the robotic pro-
cedure and other more commonly used procedures, such 
as VATS and open procedures, are still lacking. There-
fore, evaluating the long-term outcomes of patients with 
early-stage NSCLC who undergo robotic surgery, espe-
cially when compared with VATS and open procedures, 
is of considerable clinical interest.
Main text
In the recent Annals of Surgery article entitled “Long-
term survival based on the surgical approach to lobec-
tomy for clinical stage I non–small cell lung cancer: 
comparison of robotic, video assisted thoracic surgery, 
and thoracotomy lobectomy” by Yang et  al. [11], we 
compared the outcomes of patients with clinical stage I 
NSCLC who underwent robotic, VATS, and open lobec-
tomy procedures. The purpose of our study was to evalu-
ate the survival prognosis and operative morbidities of 
robotic lobectomy compared with the other two pro-
cedures [11]. We found that the 5-year overall survival 
(OS) rate for the robotic, VATS, and open lobectomy 
groups were 77.6%, 73.5%, and 77.9%, respectively; the 
differences were not statistically significant. The corre-
sponding 5-year disease-free survival (DFS) rates were 
72.7%, 65.5%, and 69.0%, respectively; here, the differ-
ence between the robotic and VATS groups was statisti-
cally significant (P =  0.047) [11]. However, multivariate 
analysis showed that surgical procedure was not an inde-
pendent factor affecting OS and DFS [11]. Operative 
morbidities, except for survival outcomes, were also 
compared. Patients who underwent robotic lobectomy 
had similar lengths of hospital stay (median, 4  days) 
compared with those who underwent VATS but shorter 
lengths of hospital stay than those who underwent an 
open procedure (median, 5 days; P < 0.001) [11]. Interest-
ingly, the robotic procedure harvested more stations of 
lymph nodes than VATS and open procedures (5 vs. 3 vs. 
4; P < 0.001) [11]. Based on these findings, we see prom-
ise in expanding patient access to robotic lung resections. 
Notably, in our study, we used propensity score matching, 
thereby minimizing the bias involved between groups.
Nevertheless, the retrospective nature of our study is a 
limitation. Considering that the preferred surgical pro-
cedure varies dramatically among surgeons operating 
on patients with NSCLC, it is very difficult to conduct 
a randomized controlled clinical trial (RCT) to compare 
the long-term outcomes of patients undergoing robotic, 
VATS, and open surgical procedures. Currently, the con-
cept of rapid rehabilitation is widely accepted. Further-
more, randomizing patients into undergoing either open 
thoracotomy or minimally invasive procedures may even 
present serious ethical concerns. Therefore, to overcome 
this limitation and to minimize bias, the best approach is 
to use a registry and prospectively collected, propensity 
score-matched data.
In China, a nationwide, unified prospective registry of 
complete clinical NSCLC data would be especially valu-
able. Unfortunately, such a registry does not currently 
exist. With increasing incidence and mortality, cancer is 
the leading cause of death in China [12]. Indeed, it was 
predicted that approximately 4,292,000 new cases of 
invasive cancer were diagnosed in 2015 [12]. In China, 
lung cancer is the most common cancer, accounting for 
approximately 17% of all cancers and constituting a major 
public health problem [12]. In today’s medical climate, 
the robot-assisted procedure for operable NSCLC faces 
two main challenges. First, it is still limited and used 
only in large-volume centers. Second, the cost of robotic 
technology, especially in a time of increasing healthcare 
expenses, may be a significant barrier. Nevertheless, 
we think that with advances in the robotic technique, 
device-related costs will decrease. Even so, we need reli-
able outcome data on which surgical procedure is best for 
operable NSCLC. Reliable data can be drawn only from 
reliable databases, and completeness is the most impor-
tant factor in achieving a high-quality database. A nation-
wide, prospectively collected NSCLC database would 
provide data of the utmost value to clinical researchers. 
Future studies that rely on such a database would benefit 
from large case numbers, complete information, minimal 
bias, good representativeness, and generalizability.
Conclusions
The study by Yang and colleagues [11] provided high-
quality data suggesting that the robotic lobectomy proce-
dure for the treatment of clinical stage I NSCLC results 
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in similar long-term survival as compared with VATS and 
thoracotomy. Robot-assisted and VATS procedures are 
associated with shorter lengths of hospital stay, and the 
robotic procedure in particular results in superior lymph 
node assessment. Further studies comparing the benefits 
and indications of the robotic procedure are warranted. 
To build on this work, we strongly recommend the devel-
opment of a high-quality, nationwide database with 
prospectively collected clinicopathologic information. 
Considering the alarming rise in the incidence of lung 
cancer in China, this database would be especially impor-
tant. It would increase the number of cases that clinical 
studies could consider, minimize bias, and would there-
fore make the data more reliable.
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